Phase I Study of JYP0322 in ROS1 Fusion-Positive Solid Tumors
Recruiting
Phase 1
Interventional Study
Protein Kinase Inhibitors
Other Protocol Specified Criteria
Lung Neoplasms
Brain Neoplasms
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
At a Glance
- Age
- 18 and older
- Sex
- Any
- Trial phase
- Phase 1
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 101 (estimated)
- Sponsor
- Guangzhou JOYO Pharma Co., Ltd · Industry
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
An open, non-randomized, multicenter, single-arm dose-escalation design, phase 1 trial to study the safety, tolerability, pharmacokinetics and efficacy of JYP0322 in patients with ROS1+ locally advanced/metastatic solid tumors .
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Key Inclusion Criteria
* Adult patients age 18 years or older.
* Histologically or cytologically confirmed diagnosis of locally advanced or metastatic solid tumors that have a ROS1 molecular fusion.
* Measurable disease according to RECIST version 1.1
* Life expectancy of at least 3 months
* Other …
Contacts
No contact information available.